Anti-PD1 antibody [NAT105] - Rabbit IgG (Chimeric),Abcam,AB216352

This rabbit monoclonal chimeric antibody has been engineered from the mouse monoclonal parent antibody Anti-PD1 antibody [NAT105] ( ab52587 ). By necessity, some mouse sequence is retained as part of the variable domain. We recommend using an Fc-directed, preadsorbed secondary antibody if multiplexing with mouse monoclonals. For example, ab150097 (AF488), ab150100 (AF594), ab150099 (AF647) or ab98467 (HRP).

Host

Rabbit

Reactivity

Human

Application

Flow Cyt (Intra), IP, IHC-P, WB

Platform ID

BAB292881172

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-PD1 antibody [NAT105] - Rabbit IgG (Chimeric)
Cat. No.AB216352
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationFlow Cyt (Intra), IP, IHC-P, WB
ClonalityMonoclonal
Clone NumberNAT105
Concentration1.03 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data The protein expressed by the gene PDCD1 functions as an inhibitory receptor on antigen-activated T-cells, playing a critical role in the induction and maintenance of immune tolerance to self. It delivers inhibitory signals by binding to the ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Tumors exploit the PDCD1-mediated inhibitory pathway to attenuate anti-tumor immunity, enabling tumor survival by evading immune system destruction. The interaction with CD274/PDCD1L1 inhibits the effector function of cytotoxic T lymphocytes (CTLs). Blocking the PDCD1-mediated pathway can reverse the exhausted T-cell phenotype and normalize the anti-tumor response, providing a rationale for cancer immunotherapy. This supplementary information is collated from multiple sources and compiled automatically. See full target information PDCD1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.